PHARMACEUTICAL FORMULATION CONTAINING TOLTERODINE AND ITS USE
The invention relates to a pharmaceutical formulation containing tolterodine or a tolterodine-related compound, or a pharmacologically acceptable salt thereof, as active ingredient, in which the formulation exhibits a controlled in vitro release of the active ingredient in phosphate buffer at pH 6.8...
Gespeichert in:
| Hauptverfasser: | , , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | RINGBERG ANDERS GREN TORKEL OLSSON BIRGITTA HALLEN BENGT WIKBERG MARTIN STROMBOM JAN NILVEBRANT LISBETH |
| description | The invention relates to a pharmaceutical formulation containing tolterodine or a tolterodine-related compound, or a pharmacologically acceptable salt thereof, as active ingredient, in which the formulation exhibits a controlled in vitro release of the active ingredient in phosphate buffer at pH 6.8 of not less than about 80 % after 18 hours, and after oral administration to a patient is capable of maintaining a substantially constant serum level of the active moiety or moieties for 24 hours. The invention also relates to the use of the pharmaceutical formulation for treating overactive bladder and gastrointestinal disorders. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_KR20070091374A</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>KR20070091374A</sourcerecordid><originalsourceid>FETCH-epo_espacenet_KR20070091374A3</originalsourceid><addsrcrecordid>eNrjZLAN8HAM8nV0dg0N8XR29FFw8w_yDfVxDPH091Nw9vcLcfT08_RzVwjx9wlxDfJ38fRzVXD0c1HwDAlWCA125WFgTUvMKU7lhdLcDMpuriHOHrqpBfnxqcUFicmpeakl8d5BRgYG5gYGlobG5iaOxsSpAgD8dir4</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>PHARMACEUTICAL FORMULATION CONTAINING TOLTERODINE AND ITS USE</title><source>esp@cenet</source><creator>RINGBERG ANDERS ; GREN TORKEL ; OLSSON BIRGITTA ; HALLEN BENGT ; WIKBERG MARTIN ; STROMBOM JAN ; NILVEBRANT LISBETH</creator><creatorcontrib>RINGBERG ANDERS ; GREN TORKEL ; OLSSON BIRGITTA ; HALLEN BENGT ; WIKBERG MARTIN ; STROMBOM JAN ; NILVEBRANT LISBETH</creatorcontrib><description>The invention relates to a pharmaceutical formulation containing tolterodine or a tolterodine-related compound, or a pharmacologically acceptable salt thereof, as active ingredient, in which the formulation exhibits a controlled in vitro release of the active ingredient in phosphate buffer at pH 6.8 of not less than about 80 % after 18 hours, and after oral administration to a patient is capable of maintaining a substantially constant serum level of the active moiety or moieties for 24 hours. The invention also relates to the use of the pharmaceutical formulation for treating overactive bladder and gastrointestinal disorders.</description><language>eng</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2007</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20070910&DB=EPODOC&CC=KR&NR=20070091374A$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,778,883,25551,76302</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20070910&DB=EPODOC&CC=KR&NR=20070091374A$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>RINGBERG ANDERS</creatorcontrib><creatorcontrib>GREN TORKEL</creatorcontrib><creatorcontrib>OLSSON BIRGITTA</creatorcontrib><creatorcontrib>HALLEN BENGT</creatorcontrib><creatorcontrib>WIKBERG MARTIN</creatorcontrib><creatorcontrib>STROMBOM JAN</creatorcontrib><creatorcontrib>NILVEBRANT LISBETH</creatorcontrib><title>PHARMACEUTICAL FORMULATION CONTAINING TOLTERODINE AND ITS USE</title><description>The invention relates to a pharmaceutical formulation containing tolterodine or a tolterodine-related compound, or a pharmacologically acceptable salt thereof, as active ingredient, in which the formulation exhibits a controlled in vitro release of the active ingredient in phosphate buffer at pH 6.8 of not less than about 80 % after 18 hours, and after oral administration to a patient is capable of maintaining a substantially constant serum level of the active moiety or moieties for 24 hours. The invention also relates to the use of the pharmaceutical formulation for treating overactive bladder and gastrointestinal disorders.</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2007</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZLAN8HAM8nV0dg0N8XR29FFw8w_yDfVxDPH091Nw9vcLcfT08_RzVwjx9wlxDfJ38fRzVXD0c1HwDAlWCA125WFgTUvMKU7lhdLcDMpuriHOHrqpBfnxqcUFicmpeakl8d5BRgYG5gYGlobG5iaOxsSpAgD8dir4</recordid><startdate>20070910</startdate><enddate>20070910</enddate><creator>RINGBERG ANDERS</creator><creator>GREN TORKEL</creator><creator>OLSSON BIRGITTA</creator><creator>HALLEN BENGT</creator><creator>WIKBERG MARTIN</creator><creator>STROMBOM JAN</creator><creator>NILVEBRANT LISBETH</creator><scope>EVB</scope></search><sort><creationdate>20070910</creationdate><title>PHARMACEUTICAL FORMULATION CONTAINING TOLTERODINE AND ITS USE</title><author>RINGBERG ANDERS ; GREN TORKEL ; OLSSON BIRGITTA ; HALLEN BENGT ; WIKBERG MARTIN ; STROMBOM JAN ; NILVEBRANT LISBETH</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_KR20070091374A3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2007</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>RINGBERG ANDERS</creatorcontrib><creatorcontrib>GREN TORKEL</creatorcontrib><creatorcontrib>OLSSON BIRGITTA</creatorcontrib><creatorcontrib>HALLEN BENGT</creatorcontrib><creatorcontrib>WIKBERG MARTIN</creatorcontrib><creatorcontrib>STROMBOM JAN</creatorcontrib><creatorcontrib>NILVEBRANT LISBETH</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>RINGBERG ANDERS</au><au>GREN TORKEL</au><au>OLSSON BIRGITTA</au><au>HALLEN BENGT</au><au>WIKBERG MARTIN</au><au>STROMBOM JAN</au><au>NILVEBRANT LISBETH</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>PHARMACEUTICAL FORMULATION CONTAINING TOLTERODINE AND ITS USE</title><date>2007-09-10</date><risdate>2007</risdate><abstract>The invention relates to a pharmaceutical formulation containing tolterodine or a tolterodine-related compound, or a pharmacologically acceptable salt thereof, as active ingredient, in which the formulation exhibits a controlled in vitro release of the active ingredient in phosphate buffer at pH 6.8 of not less than about 80 % after 18 hours, and after oral administration to a patient is capable of maintaining a substantially constant serum level of the active moiety or moieties for 24 hours. The invention also relates to the use of the pharmaceutical formulation for treating overactive bladder and gastrointestinal disorders.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng |
| recordid | cdi_epo_espacenet_KR20070091374A |
| source | esp@cenet |
| subjects | HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| title | PHARMACEUTICAL FORMULATION CONTAINING TOLTERODINE AND ITS USE |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T05%3A17%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=RINGBERG%20ANDERS&rft.date=2007-09-10&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EKR20070091374A%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |